# HIV latency reversal through novel, potent PKC modulators

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2020 · $682,208

## Abstract

   
DESCRIPTION (provided by applicant): While antiretroviral therapy (ART) has been effective in stopping or slowing disease progression for most HIV infected individuals, it is not curative. ART must instead be continuous for life, requires strict compliance, is costly, and is implicated i numerous health problems attributed to long-term chemo-exposure. Eradication of the virus would address these problems, however this has proven extremely difficult. One potential means of reducing or eliminating HIV reservoirs is to administer agents to flush the virus out of hiding while on ART, which should induce death of the cell either by virus-mediated cytotoxicity, or immune-mediated clearance. Alternatively, additional reagents specific for newly expressed viral antigens could be administered to complete this "kick and kill" strategy. Protein kinase C (PKC) modulators are among the most active HIV latency reversing agents identified to date. However, natural PKC modulators have inherent toxicities and sub-optimal potencies. This proposal brings together several laboratories with relevant expertise in chemistry, virology and animal modeling, to advance the study of synthetic PKC modulators with reduced toxicities and improved latency reversal activities through a suite of pre-clinical assessments. We will scale-up synthesis of several (already identified) improved PKC modulators, and create novel slow release versions of these compounds with the potential to further reduce toxicities. We will subject these molecules to in vitro assessment of activity in various assays including primary cells from patients on suppressive ART, and perform in vivo modeling of latency reversal in humanized mice. This in turn will inform proposed pharmacology and efficacy studies in non-human primates. Together the studies proposed herein will provide important information regarding kick and kill approaches for HIV eradication, and advance these unique and superior compounds towards clinical testing.

## Key facts

- **NIH application ID:** 9955191
- **Project number:** 5R01AI124743-05
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** PAUL Anthony WENDER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $682,208
- **Award type:** 5
- **Project period:** 2016-07-01 → 2021-08-12

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9955191

## Citation

> US National Institutes of Health, RePORTER application 9955191, HIV latency reversal through novel, potent PKC modulators (5R01AI124743-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9955191. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*